Report Back from SABCS 2023: Spotlight on the Latest in MBC
Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It’s an audio version of a live webinar that was done this past February called Report Back from San Antonio Breast Cancer Symposium 2023. SABCS is the world’s leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather. In this podcast, Dr. Timothy Pluard highlighted promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.
Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC
Today we are bringing you a special podcast that we created in partnership with SHARE Cancer Support called Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC. This episode was produced from a live webinar from this past October. There has not been a new endocrine treatment in decades and many of us find out the endocrine treatment no longer works for us because the cancer has mutated. Kate Vieira Pfitzer and Victoria Goldberg are excited to bring Dr. Virginia Kaklamani to you. You will hear her explain this common problem, how to test for it, the new treatment option that is now available as well as many of the ongoing clinical trials for HR+ MBC.
mTNBC Unicorns: Living In Contradiction
Becoming a cancer “unicorn”--a person whose cancer responds exceptionally well to available treatment and who survives beyond what is expected--is what most of us hope for. This is all the more true for triple negative MBC where effective, targeted treatments are still sorely lacking. Today we talk to two women who have lived with triple negative metastatic breast cancer for 8 years. Dr. Toni Willis and Colleen Broughton share their diagnosis & treatment stories, including their experiences with second opinions, clinical trials, self-advocacy, and cultivating joy for themselves & their families as they navigate surviving longer than they –or their doctors—expected to.
Report Back From ASCO 2023: What’s the Latest News in MBC Research?
Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Dr. Stephanie Graff: Understanding Progression
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.
Report Back from SABCS 2021: What’s the Latest in MBC Research?
Learn about the most recent information released at the annual San Antonio Breast Cancer Symposium regarding metastatic breast cancer research with Dr. Peter Schmid, Professor of Cancer Medicine at Barts Cancer Institute in London, England. Dr. Schmid will provide a comprehensive update and answer your questions about these new developments.
MBC101 - what happens when MBC spreads to the brain?
On 10/12/21 Lianne Kraemer, an MBC patient advocate living with brain mets , and SHARE hosted two brilliant young clinicians from Moffitt in a discussion on management of breast cancer brain metastases. Today we are bringing you this webinar with our additional commentary. We will let you in on a little secret. This episode is a glimpse into how we envision the next season’s Road to a Cure. It will include more content with an educational angle for the newly diagnosed or those who are ready to take a deeper dive with us into the basics. We call it MBC101.
Road to a Cure - drug resistance
It is fitting that our 7th and last stop before the SABCS is back to NYC. Co-hosts Lisa Laudico and Ellen Landsberger talk with Dr Sarat Chandarlapaty, a leading Physician Scientist at MSKCC. As both a physician treating patients and a scientist in the lab, Dr. Chandarlapaty gives us an understanding of translational medicine, transferring what he learns from his patients back into the lab to answer questions that advance the treatment of metastatic breast cancer.
Road to a Cure - ABC with Dr. Fatima Cardoso
This is the sixth stop in our series Road to a Cure. From the start our goal for this series was not only to educate and give hope to every listener but also to ensure that each of these special interviews feels like an intimate conversation with our smartest friend who also happens to be an oncologist researcher. This episode will not disappoint., Co-hosts Victoria Goldberg and Lisa Laudico, sit down with the Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, Dr. Fatima Cardoso.
Road to a Cure - ADC & SARM
How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.
Road to a Cure - use of immunotherapy
This week we are visiting Dr Stephanie Goff at the NIH in Bethesda, Maryland. Dr Goff is a surgical oncologist and a senior member of a research team led by Dr. Steven A. Rosenberg, a man widely regarded as the father of immunotherapy. A friend, who knows a thing or two about this place. is joining us on this trip. Her name is Judy Perkins, and she is the first MBC patient who has been cured by a revolutionary immunotherapy treatment, known as adoptive cell therapy, that was administered by Dr Goff and her colleagues at the NCI.
Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
Road to a Cure - Dr. Sara Hurvitz
The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes